Gland Pharma Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ra354wepnvfjt4ix4j4yuxbn.pdf

Key Takeaways


Cenexi: The Turnaround Timeline

Srinivas Sadu: “But we always knew that it will be EBITDA negative for us in terms of dilutive to Gland. But we also looked at how we can make it more efficient in a duration of time. But it took longer than what we anticipated because of the issues that we have there.”

Base Business: Steady Margin, Mixed Topline

Srinivas Sadu: “One is, of course, the new launches which will happen every quarter. That's one. Second, as I mentioned, Enoxaparin, the new contract that was signed, has not been dispatched yet. That will happen this quarter. The Civica contract, which our partner signed up. And the Saudi business is not gone. So, that will start again from this quarter.”

New Bets: Biologics CDMO and GLP-1


Product Pipeline and Capacity Expansion


Leadership and Strategic Direction

Srinivas Sadu: “I think it's more to strengthen the senior leadership to grow the business, and I'll be taking the role of more strategic and long-term - mid to long-term initiatives and also a bit more time at probably Cenexi because it needs a bit more focus.”

Guidance & Commitments

CommitmentSpecificsTimeline
Full-year revenue growthLow double-digit growth expectedFY25
U.S. top-line growthLow double-digit growthH2 FY25
Cenexi positive EBITDAAchieve positive EBITDAQ4 FY25
Cenexi EBITDA neutral / low single-digitDriven by revenue above EUR 200 million thresholdFY26
Cenexi 10% EBITDA marginAll capacity on stream, pipeline projects commercialFY27
Fontenay ampoule line commercial productionNew high-capacity line operationalJanuary 2025
Hérouville commercial productionNew inactivated vaccine and ophthalmic gelBefore end of FY25
Braine-l’Alleud lyophilizer resolutionIssue fully resolved; backup unit installedCurrent quarter / H1 2025
Enoxaparin new contract dispatchShipment to occurCurrent quarter (Q3 FY25)
Saudi business resumptionOrder pickup expectedH2 FY25
Biologics CDMO initial financial benefitsFrom Dr. Reddy’s collaborationQ1 FY26
India asset turnover recoveryNew Pashamylaram lines onstream, return to 2x–2.5xFY26 onwards
Cenexi plant utilization (two remaining plants)Technology transfers complete, commercialization operationalQ1 FY26

Key Metrics

MetricQ2 FY25
Consolidated revenue from operations₹1,405.8 cr, +2% YoY
Base business revenue growth+5% YoY
H1 FY25 consolidated revenue₹2,807.5 cr, +9% YoY
Other income₹59.6 cr (₹54.2 cr interest on fixed deposits, ₹4.5 cr forex gains)
Consolidated gross margin59%, vs 62% in Q2 FY24
Base business gross margin56%, stable
Consolidated EBITDA₹296.1 cr, 21% margin vs ₹320.5 cr and 23% margin in Q2 FY24
Base business EBITDA margin34%, similar to prior year
Net profit₹163.5 cr, -16% YoY
R&D expenditure₹49.3 cr, 4.6% of base business revenue, up from ₹35.1 cr in Q2 FY24
Effective tax rate26%
Capital expenditure₹103.7 cr, primarily for Pashamylaram modular expansion and Cenexi
Cash flow from operations (H1 FY25)₹643.6 cr
Net cash position₹2,541.3 cr (cash and equivalents ₹2,820.1 cr, after Cenexi debt)
Cash conversion cycle149 days, improved from 196 days in Q2 FY24
U.S. sales growth+3% YoY
U.S. volume growth+13% YoY, +5% QoQ
New product contribution in U.S. (H1 FY25)~₹60 cr
Rest of World revenue share19% of total revenue, similar to Q2 FY24
India market revenue₹87.4 cr, 6% of total revenue
Profit share8% of revenue excluding Cenexi
Milestone income7% of revenue excluding Cenexi
Cenexi revenue₹339.9 cr (€37 mn), -5% YoY
Cenexi gross contribution69%
Cenexi EBITDAnegative ₹68.5 cr (negative €7.5 mn)
Total U.S. ANDA filings363 filed, 304 approvals, 59 pending
Global product registrations1,726
Complex products filed9 filings completed out of 19 targeted, 6 approved and launched
Complex products IQVIA market opportunity$7.3 bn
China market approvals5 approvals out of 9 products in plan
Biologics CDMO capacity (Genome Valley)8,000 litres mammalian single-use DS capacity
Biologics CDMO site investment~₹300 cr
Biologics CDMO quarterly running cost₹3–4 cr per quarter